Hrt Financial LP Acelrx Pharmaceuticals Inc Transaction History

Hrt Financial LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.18 - $0.29 $4,866 - $7,839	-27,034 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$0.28 - $0.61 $4,769 - $10,390	17,034 Added 170.34%	27,034 $7,000
Q4 2021 Feb 14, 2022	SELL	$0.49 - $1.02 $104,247 - $217,006	-212,751 Reduced 95.51%	10,000 $5,000
Q3 2021 Nov 15, 2021	SELL	$0.93 - $1.51 $59,717 - $96,960	-64,212 Reduced 22.38%	222,751 $227,000
Q2 2021 Aug 16, 2021	BUY	$1.03 - $1.7 $295,571 - $487,837	286,963 New	286,963 $396,000
Q1 2020 May 15, 2020	SELL	$0.76 - $2.07 $36,226 - $98,668	-47,666 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$1.66 - $2.4 $52,582 - $76,022	31,676 Added 198.1%	47,666 $100,000
Q2 2018 Aug 15, 2018	BUY	$2.13 - $4.2 $34,058 - $67,158	15,990 New	15,990 $53,000

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.